Infectious complications of febrile leukopenia

Infectious Disease Clinics of North America

Volumn 15, Issue 2, 2001, Pages 457-482

  Giamarellou, Helen ^b   Antoniadou, Anastasia ^b  

^a SISMANOGLIO HOSPITAL   (Greece)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; AZLOCILLIN; CARBAPENEM DERIVATIVE; CEFPIROME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; GENTAMICIN; IMIPENEM; MACROLIDE; MEROPENEM; METRONIDAZOLE; MINOCYCLINE; PENICILLIN DERIVATIVE; PENICILLIN G; PIPERACILLIN; POSACONAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TETRACYCLINE DERIVATIVE; TICARCILLIN; VANCOMYCIN;

ANTIBIOTIC PROPHYLAXIS; CLINICAL FEATURE; FEBRILE NEUTROPENIA; GRAM POSITIVE BACTERIUM; HUMAN; INFECTION; MYCOSIS; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT;

EID: 0034959774     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5520(05)70156-2     Document Type: Article

References (71)

1. Procalcitonin in patients with and without immunosuppression and sepsis
2. Update of recommendations for the use of hematopoetic colony-stimulating factors: Evidence-based, clinical practice guidelines
3. Opportunistic mycoses in the immunocompromised host: Experience at a cancer center and review
4. Dermatologic manifestations of infections in neutropenic patients
5. Fungal infections in cancer patients: An international autopsy survey
6. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia
7. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: Ten years experience at a cancer center and implications for management
8. Improved management of invasive aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery
9. Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia
10. A survey of the use of teicoplanin in patients with haematological malignancies and solid tumors
11. New developments in the diagnosis and management of invasive fungal infections
12. Infections in patients with acute leukemia and lymphoma
13. An open study on the safety and efficacy of fluconazole in the treatment of disseminated Candida infections in patients treated for hematologic malignancy
14. Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States
15. A pilot study of antibiotic cycling in a hematology-oncology unit
16. Septicemia and shock syndrome caused by viridans streptococci: A case-control study of predisposing factors
17. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients
18. Criteria for response in patients in clinical trials of empiric antibiotic regimens for febrile neutropenia: Is there agreement?
19. Vancomycin as part of initial empirical antibiotic therapy for febrile neutropenia in patients with cancer. Pros and cons
20. Pseudomonas aeruginosa bacteremia in immunocompromised children: Analysis of factors associated with a poor outcome
21. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy
22. Empirical therapy of infections in neutropenic patients
23. Empiric therapy for infection in the febrile neutropenic compromised host
24. Infection in febrile neutropenia
25. Monotherapy with sequential high dose ciprofloxacin iv/po versus combination therapy with ceftazidime plus amikacin as initial empiric therapy in granulocytopenic patients with fever
26. Assessment of procalcitonin as a diagnostic marker of underlying infection in febrile neutropenia
27. Empiric therapy of bacterial infections in patients with severe neutropenia
28. Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia
29. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: A randomized, double-blind, double-placebo, multicenter trial comparing itraconazole with amphotericin-B
30. Guidelines from the Infectious Diseases Society of America, 1997. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever
31. Contemporary antimicrobial susceptibility patterns of bacterial pathogens commonly associated with febrile patients with neutropenia
32. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy
33. Empirical antibiotic therapy in neutropenic cancer patients
34. Science and pragmatism in the treatment and prevention of neutropenic infection
35. Empiric antimicrobial therapy for febrile granulocytopenic cancer patients: Lessons from four EORTC trials
36. Stenotrophomonas maltophilia bacteremia in cancer patients: Report on 31 cases
37. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia - Associated invasive fungal infections
38. Quantification of fungal DNA by using fluorescence resonance energy transfer and the Light Cycler system
39. Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive aspergillosis
40. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematological malignancies: A randomized, placebo-controlled, double-blind, multicenter trial
41. Fungal infections in the compromised host
42. Fungal pulmonary infections after bone marrow transplantation: Evaluation with radiography and CT
43. The diagnostic and therapeutic approach to lower respiratory tract infections in the neutropenic patient
44. Typhlitis in neutropenic patients: An analysis of thirty-nine patients in a cancer hospital
45. Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia
46. Plasma (1, 3)-β-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes
47. The changing pattern of infections in neutropenic patients
48. Current concepts: Fever in immunocompromised patients
49. In vitro activity of cefepime and ceftazidime against 197 nosocomial blood stream isolates of streptococci: A multicenter sample
50. Oral and intravenous itraconazole for systemic fungal infections in neutropenic haematological patients: Meeting report
51. Is monotherapy for febrile neutropenia still a viable alternative?
52. Expanding the options for risk-based therapy in febrile neutropenia
53. New trends in patient management: Risk-based therapy for febrile patients with neutropenia
54. Gram positive infections and the use of vancomycin in 550 episodes of fever and neutropenia
55. Empiric antibiotic therapy for granulocytopenic patients
56. Empiric antibiotic therapy for the febrile neutropenic patient: Design bias
57. Human parvovines B19-associated disease in bone marrow transplantation
58. Rare gram-positive infections in cancer patients: Study and literature review
59. Specific detection of Aspergillus species in blood and bronchoalveolar lavage samples of immunocompromised patients by two step PCR
60. Approach to fever in the neutropenic host
61. Evaluation of neutropenic fever: Value of serum and plasma parameters in clinical practice
62. Risk assessment in cancer patients with fever and neutropenia: A prospective, two-center validation of a prediction rule
63. Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: A pilot study of 30 patients based on a validated prediction rule
64. Hepatic candidiasis in cancer patients: The evolving picture of the syndrome
65. Diagnostic and therapeutic strategies for invasive aspergillosis
66. Candidaemia in cancer patients: A prospective multicenter surveillance study by the Invasive Fungal Infection Group of the EORTC
67. Emerging fungal pathogens, drug resistance and the role of lipid formulations of amphotericin B in the treatment of fungal infections in cancer patients: A review
68. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia
69. Lipid formulations of amphotericin B: Clinical efficacy and toxicities
70. Oral ciprofloxacin as antibacterial prophylaxis after allogeneic bone marrow transplantation: A reappraisal
71. Changing epidemiology of infections in patients with neutropenia and cancer: Emphasis on gram-positive and resistant bacteria